vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是REPUBLIC BANCORP INC的1.6倍（$152.6M vs $94.3M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 24.2%，领先10.3%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $44.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -11.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
CPRX vs RBCAA — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $94.3M |
| 净利润 | $52.7M | $22.8M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 29.3% |
| 净利率 | 34.5% | 24.2% |
| 营收同比 | 7.6% | 5.3% |
| 净利润同比 | -5.8% | 20.0% |
| 每股收益（稀释后） | $0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $94.3M | ||
| Q3 25 | $148.4M | $93.5M | ||
| Q2 25 | $146.6M | $93.8M | ||
| Q1 25 | $141.4M | $135.8M | ||
| Q4 24 | $141.8M | $89.5M | ||
| Q3 24 | $128.7M | $88.1M | ||
| Q2 24 | $122.7M | $86.9M | ||
| Q1 24 | $98.5M | $120.3M |
| Q4 25 | $52.7M | $22.8M | ||
| Q3 25 | $52.8M | $29.7M | ||
| Q2 25 | $52.1M | $31.5M | ||
| Q1 25 | $56.7M | $47.3M | ||
| Q4 24 | $55.9M | $19.0M | ||
| Q3 24 | $43.9M | $26.5M | ||
| Q2 24 | $40.8M | $25.2M | ||
| Q1 24 | $23.3M | $30.6M |
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
| Q4 25 | 40.5% | 29.3% | ||
| Q3 25 | 44.7% | 40.4% | ||
| Q2 25 | 45.2% | 43.0% | ||
| Q1 25 | 44.8% | 44.1% | ||
| Q4 24 | 44.3% | 25.8% | ||
| Q3 24 | 39.6% | 38.4% | ||
| Q2 24 | 44.2% | 37.0% | ||
| Q1 24 | 27.5% | 32.2% |
| Q4 25 | 34.5% | 24.2% | ||
| Q3 25 | 35.6% | 31.8% | ||
| Q2 25 | 35.6% | 33.5% | ||
| Q1 25 | 40.1% | 34.8% | ||
| Q4 24 | 39.4% | 21.2% | ||
| Q3 24 | 34.1% | 30.1% | ||
| Q2 24 | 33.2% | 29.0% | ||
| Q1 24 | 23.6% | 25.4% |
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.41 | — | ||
| Q1 25 | $0.45 | — | ||
| Q4 24 | $0.44 | — | ||
| Q3 24 | $0.35 | — | ||
| Q2 24 | $0.33 | — | ||
| Q1 24 | $0.19 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $1.1B |
| 总资产 | $1.1B | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $220.0M | ||
| Q3 25 | $689.9M | $484.2M | ||
| Q2 25 | $652.8M | $484.8M | ||
| Q1 25 | $580.7M | $793.0M | ||
| Q4 24 | $517.6M | $432.2M | ||
| Q3 24 | $442.3M | $530.9M | ||
| Q2 24 | $375.7M | $400.1M | ||
| Q1 24 | $310.4M | $546.4M |
| Q4 25 | $954.3M | $1.1B | ||
| Q3 25 | $920.2M | $1.1B | ||
| Q2 25 | $856.0M | $1.1B | ||
| Q1 25 | $794.3M | $1.0B | ||
| Q4 24 | $727.6M | $992.0M | ||
| Q3 24 | $660.9M | $979.7M | ||
| Q2 24 | $608.7M | $955.4M | ||
| Q1 24 | $561.4M | $935.6M |
| Q4 25 | $1.1B | $7.0B | ||
| Q3 25 | $1.1B | $7.0B | ||
| Q2 25 | $971.9M | $7.0B | ||
| Q1 25 | $908.9M | $7.1B | ||
| Q4 24 | $851.4M | $6.8B | ||
| Q3 24 | $772.0M | $6.7B | ||
| Q2 24 | $706.4M | $6.6B | ||
| Q1 24 | $646.7M | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $161.1M |
| 自由现金流率自由现金流/营收 | 29.4% | 170.9% |
| 资本支出强度资本支出/营收 | 0.0% | 7.5% |
| 现金转化率经营现金流/净利润 | 0.85× | 7.37× |
| 过去12个月自由现金流最近4个季度 | — | $288.6M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $168.2M | ||
| Q3 25 | $32.4M | $33.3M | ||
| Q2 25 | $71.3M | $8.4M | ||
| Q1 25 | $60.0M | $93.2M | ||
| Q4 24 | $70.9M | $149.0M | ||
| Q3 24 | $72.9M | $51.3M | ||
| Q2 24 | $64.1M | $4.0M | ||
| Q1 24 | $31.9M | $71.2M |
| Q4 25 | $44.9M | $161.1M | ||
| Q3 25 | — | $30.8M | ||
| Q2 25 | $71.3M | $5.2M | ||
| Q1 25 | — | $91.6M | ||
| Q4 24 | $70.8M | $143.2M | ||
| Q3 24 | $72.6M | $49.8M | ||
| Q2 24 | $64.1M | $2.7M | ||
| Q1 24 | $31.7M | $69.1M |
| Q4 25 | 29.4% | 170.9% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | 48.6% | 5.5% | ||
| Q1 25 | — | 67.4% | ||
| Q4 24 | 49.9% | 160.0% | ||
| Q3 24 | 56.4% | 56.5% | ||
| Q2 24 | 52.3% | 3.1% | ||
| Q1 24 | 32.2% | 57.5% |
| Q4 25 | 0.0% | 7.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 3.5% | ||
| Q1 25 | 0.0% | 1.2% | ||
| Q4 24 | 0.1% | 6.5% | ||
| Q3 24 | 0.2% | 1.7% | ||
| Q2 24 | 0.0% | 1.5% | ||
| Q1 24 | 0.2% | 1.7% |
| Q4 25 | 0.85× | 7.37× | ||
| Q3 25 | 0.61× | 1.12× | ||
| Q2 25 | 1.37× | 0.27× | ||
| Q1 25 | 1.06× | 1.97× | ||
| Q4 24 | 1.27× | 7.84× | ||
| Q3 24 | 1.66× | 1.93× | ||
| Q2 24 | 1.57× | 0.16× | ||
| Q1 24 | 1.37× | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RBCAA
暂无分部数据
